Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
14.93
-0.10 (-0.67%)
Jun 5, 2025, 10:03 AM - Market open
Takeda Pharmaceutical Revenue
In the fiscal year ending March 31, 2025, Takeda Pharmaceutical had annual revenue of 4.58T JPY with 7.45% growth. Takeda Pharmaceutical had revenue of 1.05T in the quarter ending March 31, 2025, with 0.24% growth.
Revenue (ttm)
4,581.55B JPY
Revenue Growth
+7.45%
P/S Ratio
1.53
Revenue / Employee
92,967,898 JPY
Employees
49,281
Market Cap
46.69B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4,581.55B | 317.79B | 7.45% |
| Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
| Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
| Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
| Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
TAK News
- 1 day ago - European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD - Business Wire
- 4 days ago - Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Business Wire
- 9 days ago - Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award - Business Wire
- 21 days ago - The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 - Business Wire
- 25 days ago - Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise - Seeking Alpha
- 27 days ago - Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs - Benzinga
- 4 weeks ago - Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress - Business Wire